Among these, 285 were excluded for not reporting specifically on populations with T2DM, 29 were excluded for focusing on injectable GLP-1 agonists used as monotherapy rather than in combination or comparison, and 127 were excluded due to irrelevant study design (e.g., observational studies, reviews, or animal studies). Here, GLP1R is linked to type 2 diabetes mellitus.